Sherman Diagnostics
Pathogen Detection Technology
Company Overview
Snapshot
Founded in March 2020 by Menny Sherman and Eilon Sherman, Sherman Diagnostics operates with 1–10 employees. The company has secured funding across two rounds from one investor. In May 2024, Sherman Diagnostics received follow-on funding from Sanara Ventures.
Business overview
Sherman Diagnostics develops diagnostic technology for pathogen detection using biological samples. The company's core product enables rapid, economical, and efficient testing for infectious diseases, including DNA/RNA-based pathogens like coronavirus. It serves the health tech and life sciences sectors, specifically focusing on medical devices and diagnostics, with business models spanning B2B and B2B2C.
Strategic signal
In May 2024, Sherman Diagnostics received follow-on funding from Sanara Ventures. This continued investment signals ongoing validation of the company's pathogen detection technology and its potential for market adoption in the diagnostics sector, reinforcing investor confidence in its growth trajectory.
Company Intelligence Q&A
- What is Sherman Diagnostics' core technology?
- Sherman Diagnostics has developed a diagnostic technology designed to detect pathogens using any biological sample, focusing on rapid and economical testing of infectious diseases such as coronavirus.
- When was Sherman Diagnostics founded and by whom?
- Sherman Diagnostics was founded in March 2020 by Menny Sherman and Eilon Sherman.
- Which investor has supported Sherman Diagnostics?
- Sherman Diagnostics has received funding from Sanara Ventures, with an initial investment in October 2020 and follow-on funding in May 2024.
- What markets does Sherman Diagnostics serve?
- Sherman Diagnostics operates in the health tech and life sciences sectors, with a focus on medical devices and diagnostics for both B2B and B2B2C markets.
- What is the primary application of Sherman Diagnostics' technology?
- The company's technology is primarily used for the affordable and efficient detection of DNA/RNA-based pathogens, enabling rapid testing for infectious diseases.